Subgroup analysis of the severe eosinophilia group
eosinophilia
SECONDARY, EOSINOPHILIA
A total of n=66 patients (n=29 steroid group, n=35 placebo group) were graded with severe and moderate eosinophilia. There were differences between the steroid and the placebo group concerning all primary and secondary endpoints (p>0.05). For the sinonasal symptom sense of smell, there was a significant interaction (p=0.034) with significant differences in favor of the placebo group at the time points 0.75, 3 and 12 months (p=0.042; p= 0.020; p=0.040 respectively). However, after correction for multiple hypotheses testing, the significant difference did not remain. These results were also underlined by the 16-item identification test scores using Sniffin´ Sticks, where no significant interaction was found (p=0.168)(Line plots of the subgroup analysis (high eosinophilia in tissue group) for 